OR WAIT null SECS
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
Recent FDA action (through April 2009) related to alglucosidase alfa, bosentan, cetuximab, doxepin, telavancin, quetiapine extended-release, oxycodone/niacin, and EUR-1073
Complete response
Priority review
Orphan drug designations